-
Most Recent
Search Results
240 results for abv
Party Like It’s 1999? Here’s What We Learned From Palantir’s Earnings
Palantir Technologies, Inc. (PLTR) reported incredible earnings this week, and in today’s Market 360, we’ll take a closer look at what they reveal about the…
History’s Largest Infrastructure Cycle Has Begun
Wall Street’s next megatrend is here: AI infrastructure. See which companies will win as AI capex tops $1 trillion by 2028.
3 Stocks to Buy for a Volatile End to 2025
Now, as we enter the start of a potential Santa Claus rally, I’d like to leave you with three stocks that should perform well heading…
The Power of Timing in a Global Market
A perpetual but tricky factor, timing is the key to any successful trading strategy. And coupled with timing, my strategy has always been big picture.…
ABM’s Dividend Increase Won’t Keep it Above $30
This morning I am recommending a bearish trade on ABM Industries, Inc. (NYSE:ABM), a provider of facility services like parking, janitorial services and building and…
Trade of the Day: AbbVie (ABBV)
In 2017, Humira raked in $18.9 billion in sales for AbbVie (ABBV) and, according to the company’s latest earnings announcement, that sales rate grew by…
How I Found the Quantum Revolution Early – and How to Supercharge Your Returns
In today’s Market 360, I’ll explain why quantum computing is shaping up to be the next phase of the AI Revolution and how I identified…
Strong Buy for AbbVie (ABBV) This Week
AbbVie (ABBV) remains a Strong Buy this week based on the most current relative pricing of its shares and analysis.
Strong Buy for AbbVie (ABBV) This Week
The Strong Buy for AbbVie (ABBV) this week is based on the latest stock market rankings, and relative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
AbbVie Inc (ABBV) Is About to Steamroll the Competition
Good news for AbbVie (ABBV) shareholders: The pharmaceutical company just entered the Hepatitis C. market, while reinforcing its position in the psoriasis area. Given ABBV’s…
Trade of the Day: AbbVie Inc. (NYSE:ABBV)
AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.
Hold Recommendation for AbbVie (ABBV) Stock Kept
Currently, AbbVie Inc (NYSE:ABBV) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change…
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
AbbVie’s quarterly results were roughly in line with Wall Street’s expectations, but ABBV stock still slipped in early trading.
AbbVie Inc (ABBV) Earnings: 12 Things to Know
AbbVie (ABBV) has released its earnings report for the third quarter of 2017 and ‘InvestorPlace’ has a few things to know about it.
Superior Earnings Momentum Keeps AbbVie (ABBV) a Buy
AbbVie Inc (NYSE:ABBV) is one of 345 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health…
6 – 10 of 240 results
